1.15
전일 마감가:
$1.13
열려 있는:
$1.14
하루 거래량:
838.74K
Relative Volume:
0.45
시가총액:
$131.79M
수익:
$13.45M
순이익/손실:
$-178.23M
주가수익비율:
-0.697
EPS:
-1.65
순현금흐름:
$-132.53M
1주 성능:
+0.88%
1개월 성능:
-3.36%
6개월 성능:
-12.88%
1년 성능:
-73.07%
Fate Therapeutics Inc Stock (FATE) Company Profile
명칭
Fate Therapeutics Inc
전화
858.875.1803
주소
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
FATE을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
FATE
Fate Therapeutics Inc
|
1.15 | 130.68M | 13.45M | -178.23M | -132.53M | -1.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-11-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
2024-06-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2023-03-27 | 재개 | Wells Fargo | Equal Weight |
2023-01-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
2023-01-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
2023-01-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2023-01-06 | 다운그레이드 | Stifel | Buy → Hold |
2023-01-06 | 다운그레이드 | Truist | Buy → Hold |
2023-01-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
2023-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2022-12-15 | 개시 | Goldman | Sell |
2022-11-04 | 재개 | Cantor Fitzgerald | Overweight |
2022-10-10 | 개시 | Canaccord Genuity | Buy |
2022-08-18 | 재개 | Wells Fargo | Overweight |
2022-07-28 | 개시 | Needham | Hold |
2022-07-11 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2022-06-03 | 개시 | Robert W. Baird | Neutral |
2022-02-11 | 재개 | BMO Capital Markets | Market Perform |
2021-12-15 | 업그레이드 | Wedbush | Neutral → Outperform |
2021-12-07 | 개시 | Cowen | Outperform |
2021-11-09 | 업그레이드 | Citigroup | Neutral → Buy |
2021-08-26 | 개시 | Morgan Stanley | Equal-Weight |
2021-06-07 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2021-05-07 | 업그레이드 | Wedbush | Neutral → Outperform |
2021-04-26 | 재개 | Jefferies | Buy |
2021-02-26 | 개시 | BofA Securities | Buy |
2021-02-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
2021-02-11 | 다운그레이드 | Citigroup | Buy → Neutral |
2021-01-27 | 재개 | H.C. Wainwright | Neutral |
2020-05-13 | 개시 | H.C. Wainwright | Buy |
2020-03-04 | 개시 | Barclays | Overweight |
2020-01-09 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2019-12-30 | 재확인 | Mizuho | Buy |
2019-12-09 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
2019-11-12 | 개시 | SunTrust | Buy |
2019-11-06 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
2019-10-01 | 개시 | Stifel | Buy |
2019-08-09 | 개시 | BTIG Research | Buy |
2019-07-22 | 개시 | Cantor Fitzgerald | Overweight |
2019-07-12 | 개시 | Oppenheimer | Outperform |
2019-06-13 | 개시 | Mizuho | Buy |
2019-06-07 | 개시 | ROTH Capital | Neutral |
2019-05-31 | 개시 | Guggenheim | Buy |
2019-05-24 | 재개 | Citigroup | Buy |
2019-03-28 | 개시 | SVB Leerink | Outperform |
2019-01-03 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
2018-11-05 | 개시 | Jefferies | Buy |
2018-08-01 | 개시 | Citigroup | Buy |
2018-03-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
모두보기
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
What drives Fate Therapeutics Inc. stock priceUnstoppable trading performance - Autocar Professional
Is Fate Therapeutics Inc. a good long term investmentFree Investment Portfolio Suggestions - Autocar Professional
Fate Therapeutics Inc. Stock Analysis and ForecastFree Investment Community - jammulinksnews.com
What analysts say about Fate Therapeutics Inc. stockUnbelievable profit margins - jammulinksnews.com
why fate therapeutics inc. stock attracts strong analyst attentionFree Day Trading Recommendations - Newser
what makes fate therapeutics inc. stock price move sharplyIntraday Trade Ideas - Newser
Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data - MSN
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of “Hold” from Brokerages - Defense World
How Fate Therapeutics Inc. stock performs during market volatilityMarket Beating Strategy - Newser
Why Fate Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser
What makes Fate Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser
We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully - Yahoo Finance
10 Best Get Rich Quick Stocks to Buy Now - Insider Monkey
Research Analysts Offer Predictions for FATE Q2 Earnings - Defense World
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics shares rise 3.57% after-hours after granting non-qualified stock options to a new employee. - AInvest
H.C. Wainwright maintains Neutral rating on Fate Therapeutics stock at $5 - Investing.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) added to Russell Microcap Value Index - MarketScreener
Fate Therapeutics (NASDAQ:FATE) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Institutional owners may take dramatic actions as Fate Therapeutics, Inc.'s (NASDAQ:FATE) recent 20% drop adds to one-year losses - simplywall.st
Fate Therapeutics’ SWOT analysis: promising data boosts stock outlook - Investing.com
TC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical Review - Defense World
Fate Therapeutics (NASDAQ:FATE) Given “Hold” Rating at Needham & Company LLC - Defense World
FATE: Analyst Maintains Hold Rating on Fate Therapeutics | FATE Stock News - GuruFocus
Needham maintains hold on Fate Therapeutics stock despite lupus data By Investing.com - Investing.com Canada
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? - Yahoo Finance
Fate Therapeutics price target lowered to $2.20 by BofA on SLE data - Investing.com Canada
Fate Therapeutics (FATE) Shares Promising Data on FT819 for Lupus Treatment | FATE Stock News - GuruFocus
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - The Manila Times
Fate Therapeutics Reports Promising Clinical Data for FT819 in Treating Severe Lupus Nephritis at EULAR 2025 - Nasdaq
Fate’s FT819 shows promising results in lupus patients - Investing.com
Breakthrough: Fate's Off-the-Shelf CAR T-Cell Shows 100% Response Rate in Severe Lupus Patients - Stock Titan
Squarepoint Ops LLC Purchases 20,805 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Bank of America Corp DE Sells 550,066 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Cantor Fitzgerald Comments on FATE FY2026 Earnings - Defense World
Top Cancer Stocks to Supercharge Your 2025 Portfolio - Yahoo Finance
Two Sigma Investments LP Cuts Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Jane Street Group LLC Has $51,000 Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Millennium Management LLC Increases Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Ameriprise Financial Inc. Sells 72,581 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Public Employees Retirement System of Ohio Sells 46,100 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Inc (NASDAQ:FATE) Price Forecast For The Next 12 Months Is Set At 3. - Marketing Sentinel
ProShare Advisors LLC Has $56,000 Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Inc (FATE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):